Victoza Injection
Product Images NDC 50090-2853

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Victoza (NDC 50090-2853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)

Chemical structure diagram representing the peptide sequence of liraglutide with labeled amino acids and a C-16 fatty acid (palmitoyl) attached, illustrating its molecular composition related to the active ingredient in Victoza injection.*

FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)

A line graph comparing the insulin secretion rate (ISR) in pmol/kg/min versus plasma glucose concentration in mg/dL for Victoza (liraglutide) injection at 6 mg/mL and placebo. Data points for Victoza are represented by dark purple diamonds, showing higher ISR values across increasing plasma glucose levels compared to the gray triangles representing placebo.*

FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)

A line chart comparing mean HbA1c percentages over 26 weeks for Victoza injection at 1.2 mg and 1.8 mg doses versus Sitagliptin 100 mg. The x-axis shows time in weeks, and the y-axis shows mean HbA1c percentage. Both Victoza doses show greater HbA1c reduction compared to Sitagliptin.*

FDA Label Image

Victoza Pen And Needle (Image 01)

Illustration of the Victoza Pen injection device and needle components. The pen is labeled with parts including pen cap, rubber stopper, cartridge tip, cartridge scale, cartridge, dose display, dose selector, pointer, dose button, and flow check symbol. The needle section shows outer needle cap, inner needle cap, needle, and protective tab, with a support phone number and website for user assistance.*

FDA Label Image

Fig. A (Pull off pen cap)

An instructional illustration showing a close-up of a hand holding a blue injection pen with a slider component being pushed in the direction indicated by a blue arrow. The image appears to demonstrate a step in using the Victoza (liraglutide) subcutaneous injection pen.*

FDA Label Image

Fig. B (Remove protective tab.)

An instructional diagram showing a hand holding a Victoza injection pen, with an arrow indicating a twist or turn motion on the pen's dial. This image is likely part of administration instructions for the Victoza 6 mg/mL subcutaneous injection by A-S Medication Solutions.*

FDA Label Image

Fig. C And D (- Image 04)

An illustration showing two steps (labeled C and D) in preparing an injection device. The first step (C) depicts a hand pulling off the cap from the needle, and the second step (D) shows a hand removing a protective shield from the needle tip, indicating preparation for subcutaneous injection.*

FDA Label Image

Fig. E (Image 05)

An instructional diagram showing hands holding a blue liraglutide injection pen device labeled Victoza. The diagram highlights the 'flow check' symbol selection step, indicating the position to ensure flow through the device before injection.*

FDA Label Image

Fig. F (Image 06)

An instructional illustration showing a finger pressing down on the top of a prefilled injection pen. The image likely demonstrates how to activate or use the injection pen for subcutaneous administration.*

FDA Label Image

Fig. G (Image 07)

Illustration showing a hand operating a Victoza liraglutide injection pen. The image highlights lifting the dose selector from the base of the pen with an upward arrow and a close-up of the dose display showing zero units, indicating the injection pen setup for dose selection.*

FDA Label Image

Fig. H (Pull off pen cap.)

Illustration showing a close-up of a person holding a Victoza injection pen. The image highlights a hand pulling back a part of the pen, indicated by a blue arrow, suggesting an action to prepare the subcutaneous injection for use.*

FDA Label Image

Fig. I (Image 09)

An instructional illustration showing a hand removing the cap from an injection pen, labeled with the number '1' in the top left corner, indicating the first step in preparing the Victoza (liraglutide) subcutaneous injection device for use.*

FDA Label Image

Fig. J-k (Image 10)

Instructional illustration demonstrating the removal of the cap from a Victoza 6 mg/mL subcutaneous injection pen. The two-step graphic shows fingers twisting and pulling the cap off the pen prior to use.*

FDA Label Image

Fig. L (Image 11)

An instructional illustration showing a hand adjusting a dial on a Victoza injection pen to select the dosage. Below the image, three selectable dose options are displayed: 0.6 mg, 1.2 mg, and 1.8 mg, with 0.6 mg currently selected.*

FDA Label Image

Fig. M (Image 12)

An instructional illustration showing a hand holding a Victoza 6 mg/mL injection pen for subcutaneous use. The image demonstrates pressing down on the top of the pen, with a close-up inset showing the dose indicator set to 0, indicating preparation or dose selection.*

FDA Label Image

Fig. N (Image 13)

An instructional illustration showing a hand holding a Victoza (liraglutide) injection pen vertically with the needle downward, positioned above a surface. A downward arrow indicates the pen should point down, and a stopwatch displays the number 6, suggesting a timing instruction likely related to injection or priming. The image includes a small 'N' symbol in the top left corner.*

FDA Label Image

Fig. O (Image 14)

An instructional illustration showing a syringe needle pointing downward with a large blue arrow pointing upward above it, likely indicating a step to withdraw or pull back the syringe before injection.*

FDA Label Image

Fig. P (Image 15)

An instructional illustration showing the removal of a cap from a medical injection device or syringe. A blue arrow points left indicating the direction to pull the cap off before use.*

FDA Label Image

Fig. Q (Image 16)

An instructional illustration showing a hand adjusting or holding the dosing mechanism of a Victoza (liraglutide) injection pen. The image includes an arrow indicating the direction for operating the pen, likely part of usage or dosing instructions.*

FDA Label Image

Figure 5 (Image 20)

A Kaplan-Meier curve chart comparing the percentage of patients with an event over time (months) between Victoza and placebo groups. The x-axis shows time from randomization in months, and the y-axis shows the percent of patients with an event. The chart includes patient counts at risk for both groups at various time points and reports a hazard ratio (HR) of 0.87 with a 95% confidence interval of 0.78 to 0.97.*

FDA Label Image

Figure 3 (Image 21)

A line chart showing mean HbA1c (%) over time (weeks) for three groups: Glimepiride, Victoza 1.2 mg, and Victoza 1.8 mg. The X-axis represents time in weeks (0 to 52), and the Y-axis represents mean HbA1c percentage. Data points indicate a decrease in HbA1c levels over the study period for both Victoza dosages compared to Glimepiride.*

FDA Label Image

Label Image (Lbl500902853)

Victoza 6 mg/mL (liraglutide) injection packaging label by A-S Medication Solutions. The label indicates a subcutaneous injection with 3 pens per package. It includes dosing instructions, storage information to refrigerate and not freeze, and distributor details in Libertyville, Illinois. The NDC is 50090-2853-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.